NCT03595917 2025-11-04ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLDana-Farber Cancer InstitutePhase 1 Recruiting40 enrolled
NCT04925479 2025-09-17Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaNovartisPhase 1/2 Recruiting44 enrolled
NCT04838041 2025-07-30Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationMedical College of WisconsinPhase 2 Recruiting51 enrolled
NCT06409936 2025-07-08PEARLGruppo Italiano Malattie EMatologiche dell'AdultoPhase 2 Recruiting160 enrolled